Cargando…

The challenge of describing the epidemiology of HTLV in the Amazon region of Brazil

HTLV-1 was the first described human retrovirus and was soon found to be associated with severe clinical diseases, including a devastating lymphoma/leukemia and other inflammatory diseases. Although HTLV-2 is not usually pathogenic, it is widely distributed among native Indian populations in Brazil,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishak, Ricardo, de Oliveira Guimarães Ishak, Marluísa, Vallinoto, Antonio Carlos R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023703/
https://www.ncbi.nlm.nih.gov/pubmed/32059740
http://dx.doi.org/10.1186/s12977-020-0512-z
_version_ 1783498307917578240
author Ishak, Ricardo
de Oliveira Guimarães Ishak, Marluísa
Vallinoto, Antonio Carlos R.
author_facet Ishak, Ricardo
de Oliveira Guimarães Ishak, Marluísa
Vallinoto, Antonio Carlos R.
author_sort Ishak, Ricardo
collection PubMed
description HTLV-1 was the first described human retrovirus and was soon found to be associated with severe clinical diseases, including a devastating lymphoma/leukemia and other inflammatory diseases. Although HTLV-2 is not usually pathogenic, it is widely distributed among native Indian populations in Brazil, particularly in the Amazon region of the country. Presently, HTLV spreads mainly by the sexual route and from mother to child, and virus persistence is an active biological factor aiding its transmission. Recently, the use of illicit drugs has been shown to be an additional risk factor, showing the influence of new habits on the epidemiology of HTLV in the region. Despite the detection of the virus in several different populations in the Amazon region of Brazil for almost 30 years, the exact prevalence of HTLV-1/2 is not well defined. The original biases in sampling and the selection of epidemiologically unsuitable populations were commonly repeated in most prevalence studies, generating unreliable and conflicting figures that do not represent the actual prevalence of HTLV. The improvements in clinical and laboratory facilities have resulted in the description of several clinical manifestations that were previously unknown in the region. The extent of the spread of the virus must be defined in this region, which is the largest geographical area of the country. As prophylaxis advances toward the use of vaccines against HTLV-1, it is important to determine who is at risk of being infected and developing a disease to successfully implement preventive measures, particularly as proposals are made to eradicate the virus among humans.
format Online
Article
Text
id pubmed-7023703
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70237032020-02-20 The challenge of describing the epidemiology of HTLV in the Amazon region of Brazil Ishak, Ricardo de Oliveira Guimarães Ishak, Marluísa Vallinoto, Antonio Carlos R. Retrovirology Review HTLV-1 was the first described human retrovirus and was soon found to be associated with severe clinical diseases, including a devastating lymphoma/leukemia and other inflammatory diseases. Although HTLV-2 is not usually pathogenic, it is widely distributed among native Indian populations in Brazil, particularly in the Amazon region of the country. Presently, HTLV spreads mainly by the sexual route and from mother to child, and virus persistence is an active biological factor aiding its transmission. Recently, the use of illicit drugs has been shown to be an additional risk factor, showing the influence of new habits on the epidemiology of HTLV in the region. Despite the detection of the virus in several different populations in the Amazon region of Brazil for almost 30 years, the exact prevalence of HTLV-1/2 is not well defined. The original biases in sampling and the selection of epidemiologically unsuitable populations were commonly repeated in most prevalence studies, generating unreliable and conflicting figures that do not represent the actual prevalence of HTLV. The improvements in clinical and laboratory facilities have resulted in the description of several clinical manifestations that were previously unknown in the region. The extent of the spread of the virus must be defined in this region, which is the largest geographical area of the country. As prophylaxis advances toward the use of vaccines against HTLV-1, it is important to determine who is at risk of being infected and developing a disease to successfully implement preventive measures, particularly as proposals are made to eradicate the virus among humans. BioMed Central 2020-02-14 /pmc/articles/PMC7023703/ /pubmed/32059740 http://dx.doi.org/10.1186/s12977-020-0512-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Ishak, Ricardo
de Oliveira Guimarães Ishak, Marluísa
Vallinoto, Antonio Carlos R.
The challenge of describing the epidemiology of HTLV in the Amazon region of Brazil
title The challenge of describing the epidemiology of HTLV in the Amazon region of Brazil
title_full The challenge of describing the epidemiology of HTLV in the Amazon region of Brazil
title_fullStr The challenge of describing the epidemiology of HTLV in the Amazon region of Brazil
title_full_unstemmed The challenge of describing the epidemiology of HTLV in the Amazon region of Brazil
title_short The challenge of describing the epidemiology of HTLV in the Amazon region of Brazil
title_sort challenge of describing the epidemiology of htlv in the amazon region of brazil
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023703/
https://www.ncbi.nlm.nih.gov/pubmed/32059740
http://dx.doi.org/10.1186/s12977-020-0512-z
work_keys_str_mv AT ishakricardo thechallengeofdescribingtheepidemiologyofhtlvintheamazonregionofbrazil
AT deoliveiraguimaraesishakmarluisa thechallengeofdescribingtheepidemiologyofhtlvintheamazonregionofbrazil
AT vallinotoantoniocarlosr thechallengeofdescribingtheepidemiologyofhtlvintheamazonregionofbrazil
AT ishakricardo challengeofdescribingtheepidemiologyofhtlvintheamazonregionofbrazil
AT deoliveiraguimaraesishakmarluisa challengeofdescribingtheepidemiologyofhtlvintheamazonregionofbrazil
AT vallinotoantoniocarlosr challengeofdescribingtheepidemiologyofhtlvintheamazonregionofbrazil